Poly ADP-ribose polymerase (PARP) is a DNA repair enzyme involved in the single-strand repair process of DNA. PARP inhibitors (PARPi) inhibit PARP activity through two mechanisms: direct inhibition of PARP function and PARP trapping, resulting in the stalling and collapse of replication forks, resulting in fatal double-strand breaks. Normal cells can repair double-strand breaks in time and correctly through homologous recombination repair (HRR); however, in tumor cells carrying HRR gene mutations, due to the impairment or loss of HRR function, the accumulated double-strand breaks will not be repaired in time and correctly, resulting in The tumor cell genome is unstable and eventually induces tumor cell death.

The global market for Prostate Cancer PARP Inhibitor Drugs was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Prostate Cancer PARP Inhibitor Drugs, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Prostate Cancer PARP Inhibitor Drugs by region & country, by Type, and by Application.

The Prostate Cancer PARP Inhibitor Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Prostate Cancer PARP Inhibitor Drugs.

Market Segmentation

Scope of Prostate Cancer PARP Inhibitor Drugs - Market Report

Report Metric	Details
Report Name	Prostate Cancer PARP Inhibitor Drugs - Market
CAGR	5%
Segment by Type:	Lynparza Zejula Talzenna Fluzoparib PamiPali Other
Segment by Application	Hospital Specialty Clinic other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	AstraZeneca, Merck & Co., Inc, GSK, Pfizer, Johnson & Johnson, Takeda Pharmaceutical Company Limited, BeiGene, Inc, Jiangsu Hengrui Pharmaceuticals Co., Ltd
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Prostate Cancer PARP Inhibitor Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Prostate Cancer PARP Inhibitor Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Prostate Cancer PARP Inhibitor Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Prostate Cancer PARP Inhibitor Drugs - Market report?

Ans: The main players in the Prostate Cancer PARP Inhibitor Drugs - Market are AstraZeneca, Merck & Co., Inc, GSK, Pfizer, Johnson & Johnson, Takeda Pharmaceutical Company Limited, BeiGene, Inc, Jiangsu Hengrui Pharmaceuticals Co., Ltd

What are the Application segmentation covered in the Prostate Cancer PARP Inhibitor Drugs - Market report?

Ans: The Applications covered in the Prostate Cancer PARP Inhibitor Drugs - Market report are Hospital, Specialty Clinic, other

What are the Type segmentation covered in the Prostate Cancer PARP Inhibitor Drugs - Market report?

Ans: The Types covered in the Prostate Cancer PARP Inhibitor Drugs - Market report are Lynparza, Zejula, Talzenna, Fluzoparib, PamiPali, Other

1 Market Overview

1.1 Prostate Cancer PARP Inhibitor Drugs Product Introduction

1.2 Global Prostate Cancer PARP Inhibitor Drugs Market Size Forecast

1.2.1 Global Prostate Cancer PARP Inhibitor Drugs Sales Value (2019-2030)

1.2.2 Global Prostate Cancer PARP Inhibitor Drugs Sales Volume (2019-2030)

1.2.3 Global Prostate Cancer PARP Inhibitor Drugs Sales Price (2019-2030)

1.3 Prostate Cancer PARP Inhibitor Drugs Market Trends & Drivers

1.3.1 Prostate Cancer PARP Inhibitor Drugs Industry Trends

1.3.2 Prostate Cancer PARP Inhibitor Drugs Market Drivers & Opportunity

1.3.3 Prostate Cancer PARP Inhibitor Drugs Market Challenges

1.3.4 Prostate Cancer PARP Inhibitor Drugs Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Prostate Cancer PARP Inhibitor Drugs Players Revenue Ranking (2023)

2.2 Global Prostate Cancer PARP Inhibitor Drugs Revenue by Company (2019-2024)

2.3 Global Prostate Cancer PARP Inhibitor Drugs Players Sales Volume Ranking (2023)

2.4 Global Prostate Cancer PARP Inhibitor Drugs Sales Volume by Company Players (2019-2024)

2.5 Global Prostate Cancer PARP Inhibitor Drugs Average Price by Company (2019-2024)

2.6 Key Manufacturers Prostate Cancer PARP Inhibitor Drugs Manufacturing Base Distribution and Headquarters

2.7 Key Manufacturers Prostate Cancer PARP Inhibitor Drugs Product Offered

2.8 Key Manufacturers Time to Begin Mass Production of Prostate Cancer PARP Inhibitor Drugs

2.9 Prostate Cancer PARP Inhibitor Drugs Market Competitive Analysis

2.9.1 Prostate Cancer PARP Inhibitor Drugs Market Concentration Rate (2019-2024)

2.9.2 Global 5 and 10 Largest Manufacturers by Prostate Cancer PARP Inhibitor Drugs Revenue in 2023

2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Prostate Cancer PARP Inhibitor Drugs as of 2023)

2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Lynparza

3.1.2 Zejula

3.1.3 Talzenna

3.1.4 Fluzoparib

3.1.5 PamiPali

3.1.6 Other

3.2 Global Prostate Cancer PARP Inhibitor Drugs Sales Value by Type

3.2.1 Global Prostate Cancer PARP Inhibitor Drugs Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Prostate Cancer PARP Inhibitor Drugs Sales Value, by Type (2019-2030)

3.2.3 Global Prostate Cancer PARP Inhibitor Drugs Sales Value, by Type (%) (2019-2030)

3.3 Global Prostate Cancer PARP Inhibitor Drugs Sales Volume by Type

3.3.1 Global Prostate Cancer PARP Inhibitor Drugs Sales Volume by Type (2019 VS 2023 VS 2030)

3.3.2 Global Prostate Cancer PARP Inhibitor Drugs Sales Volume, by Type (2019-2030)

3.3.3 Global Prostate Cancer PARP Inhibitor Drugs Sales Volume, by Type (%) (2019-2030)

3.4 Global Prostate Cancer PARP Inhibitor Drugs Average Price by Type (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospital

4.1.2 Specialty Clinic

4.1.3 other

4.2 Global Prostate Cancer PARP Inhibitor Drugs Sales Value by Application

4.2.1 Global Prostate Cancer PARP Inhibitor Drugs Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Prostate Cancer PARP Inhibitor Drugs Sales Value, by Application (2019-2030)

4.2.3 Global Prostate Cancer PARP Inhibitor Drugs Sales Value, by Application (%) (2019-2030)

4.3 Global Prostate Cancer PARP Inhibitor Drugs Sales Volume by Application

4.3.1 Global Prostate Cancer PARP Inhibitor Drugs Sales Volume by Application (2019 VS 2023 VS 2030)

4.3.2 Global Prostate Cancer PARP Inhibitor Drugs Sales Volume, by Application (2019-2030)

4.3.3 Global Prostate Cancer PARP Inhibitor Drugs Sales Volume, by Application (%) (2019-2030)

4.4 Global Prostate Cancer PARP Inhibitor Drugs Average Price by Application (2019-2030)

5 Segmentation by Region

5.1 Global Prostate Cancer PARP Inhibitor Drugs Sales Value by Region

5.1.1 Global Prostate Cancer PARP Inhibitor Drugs Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Prostate Cancer PARP Inhibitor Drugs Sales Value by Region (2019-2024)

5.1.3 Global Prostate Cancer PARP Inhibitor Drugs Sales Value by Region (2025-2030)

5.1.4 Global Prostate Cancer PARP Inhibitor Drugs Sales Value by Region (%), (2019-2030)

5.2 Global Prostate Cancer PARP Inhibitor Drugs Sales Volume by Region

5.2.1 Global Prostate Cancer PARP Inhibitor Drugs Sales Volume by Region: 2019 VS 2023 VS 2030

5.2.2 Global Prostate Cancer PARP Inhibitor Drugs Sales Volume by Region (2019-2024)

5.2.3 Global Prostate Cancer PARP Inhibitor Drugs Sales Volume by Region (2025-2030)

5.2.4 Global Prostate Cancer PARP Inhibitor Drugs Sales Volume by Region (%), (2019-2030)

5.3 Global Prostate Cancer PARP Inhibitor Drugs Average Price by Region (2019-2030)

5.4 North America

5.4.1 North America Prostate Cancer PARP Inhibitor Drugs Sales Value, 2019-2030

5.4.2 North America Prostate Cancer PARP Inhibitor Drugs Sales Value by Country (%), 2023 VS 2030

5.5 Europe

5.5.1 Europe Prostate Cancer PARP Inhibitor Drugs Sales Value, 2019-2030

5.5.2 Europe Prostate Cancer PARP Inhibitor Drugs Sales Value by Country (%), 2023 VS 2030

5.6 Asia Pacific

5.6.1 Asia Pacific Prostate Cancer PARP Inhibitor Drugs Sales Value, 2019-2030

5.6.2 Asia Pacific Prostate Cancer PARP Inhibitor Drugs Sales Value by Country (%), 2023 VS 2030

5.7 South America

5.7.1 South America Prostate Cancer PARP Inhibitor Drugs Sales Value, 2019-2030

5.7.2 South America Prostate Cancer PARP Inhibitor Drugs Sales Value by Country (%), 2023 VS 2030

5.8 Middle East & Africa

5.8.1 Middle East & Africa Prostate Cancer PARP Inhibitor Drugs Sales Value, 2019-2030

5.8.2 Middle East & Africa Prostate Cancer PARP Inhibitor Drugs Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Prostate Cancer PARP Inhibitor Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Prostate Cancer PARP Inhibitor Drugs Sales Value

6.2.1 Key Countries/Regions Prostate Cancer PARP Inhibitor Drugs Sales Value, 2019-2030

6.2.2 Key Countries/Regions Prostate Cancer PARP Inhibitor Drugs Sales Volume, 2019-2030

6.3 United States

6.3.1 United States Prostate Cancer PARP Inhibitor Drugs Sales Value, 2019-2030

6.3.2 United States Prostate Cancer PARP Inhibitor Drugs Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Prostate Cancer PARP Inhibitor Drugs Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Prostate Cancer PARP Inhibitor Drugs Sales Value, 2019-2030

6.4.2 Europe Prostate Cancer PARP Inhibitor Drugs Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Prostate Cancer PARP Inhibitor Drugs Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Prostate Cancer PARP Inhibitor Drugs Sales Value, 2019-2030

6.5.2 China Prostate Cancer PARP Inhibitor Drugs Sales Value by Type (%), 2023 VS 2030

6.5.3 China Prostate Cancer PARP Inhibitor Drugs Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Prostate Cancer PARP Inhibitor Drugs Sales Value, 2019-2030

6.6.2 Japan Prostate Cancer PARP Inhibitor Drugs Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Prostate Cancer PARP Inhibitor Drugs Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Prostate Cancer PARP Inhibitor Drugs Sales Value, 2019-2030

6.7.2 South Korea Prostate Cancer PARP Inhibitor Drugs Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Prostate Cancer PARP Inhibitor Drugs Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Prostate Cancer PARP Inhibitor Drugs Sales Value, 2019-2030

6.8.2 Southeast Asia Prostate Cancer PARP Inhibitor Drugs Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Prostate Cancer PARP Inhibitor Drugs Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Prostate Cancer PARP Inhibitor Drugs Sales Value, 2019-2030

6.9.2 India Prostate Cancer PARP Inhibitor Drugs Sales Value by Type (%), 2023 VS 2030

6.9.3 India Prostate Cancer PARP Inhibitor Drugs Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 AstraZeneca

7.1.1 AstraZeneca Company Information

7.1.2 AstraZeneca Introduction and Business Overview

7.1.3 AstraZeneca Prostate Cancer PARP Inhibitor Drugs Sales, Revenue and Gross Margin (2019-2024)

7.1.4 AstraZeneca Prostate Cancer PARP Inhibitor Drugs Product Offerings

7.1.5 AstraZeneca Recent Development

7.2 Merck & Co., Inc

7.2.1 Merck & Co., Inc Company Information

7.2.2 Merck & Co., Inc Introduction and Business Overview

7.2.3 Merck & Co., Inc Prostate Cancer PARP Inhibitor Drugs Sales, Revenue and Gross Margin (2019-2024)

7.2.4 Merck & Co., Inc Prostate Cancer PARP Inhibitor Drugs Product Offerings

7.2.5 Merck & Co., Inc Recent Development

7.3 GSK

7.3.1 GSK Company Information

7.3.2 GSK Introduction and Business Overview

7.3.3 GSK Prostate Cancer PARP Inhibitor Drugs Sales, Revenue and Gross Margin (2019-2024)

7.3.4 GSK Prostate Cancer PARP Inhibitor Drugs Product Offerings

7.3.5 GSK Recent Development

7.4 Pfizer

7.4.1 Pfizer Company Information

7.4.2 Pfizer Introduction and Business Overview

7.4.3 Pfizer Prostate Cancer PARP Inhibitor Drugs Sales, Revenue and Gross Margin (2019-2024)

7.4.4 Pfizer Prostate Cancer PARP Inhibitor Drugs Product Offerings

7.4.5 Pfizer Recent Development

7.5 Johnson & Johnson

7.5.1 Johnson & Johnson Company Information

7.5.2 Johnson & Johnson Introduction and Business Overview

7.5.3 Johnson & Johnson Prostate Cancer PARP Inhibitor Drugs Sales, Revenue and Gross Margin (2019-2024)

7.5.4 Johnson & Johnson Prostate Cancer PARP Inhibitor Drugs Product Offerings

7.5.5 Johnson & Johnson Recent Development

7.6 Takeda Pharmaceutical Company Limited

7.6.1 Takeda Pharmaceutical Company Limited Company Information

7.6.2 Takeda Pharmaceutical Company Limited Introduction and Business Overview

7.6.3 Takeda Pharmaceutical Company Limited Prostate Cancer PARP Inhibitor Drugs Sales, Revenue and Gross Margin (2019-2024)

7.6.4 Takeda Pharmaceutical Company Limited Prostate Cancer PARP Inhibitor Drugs Product Offerings

7.6.5 Takeda Pharmaceutical Company Limited Recent Development

7.7 BeiGene, Inc

7.7.1 BeiGene, Inc Company Information

7.7.2 BeiGene, Inc Introduction and Business Overview

7.7.3 BeiGene, Inc Prostate Cancer PARP Inhibitor Drugs Sales, Revenue and Gross Margin (2019-2024)

7.7.4 BeiGene, Inc Prostate Cancer PARP Inhibitor Drugs Product Offerings

7.7.5 BeiGene, Inc Recent Development

7.8 Jiangsu Hengrui Pharmaceuticals Co., Ltd

7.8.1 Jiangsu Hengrui Pharmaceuticals Co., Ltd Company Information

7.8.2 Jiangsu Hengrui Pharmaceuticals Co., Ltd Introduction and Business Overview

7.8.3 Jiangsu Hengrui Pharmaceuticals Co., Ltd Prostate Cancer PARP Inhibitor Drugs Sales, Revenue and Gross Margin (2019-2024)

7.8.4 Jiangsu Hengrui Pharmaceuticals Co., Ltd Prostate Cancer PARP Inhibitor Drugs Product Offerings

7.8.5 Jiangsu Hengrui Pharmaceuticals Co., Ltd Recent Development

8 Industry Chain Analysis

8.1 Prostate Cancer PARP Inhibitor Drugs Industrial Chain

8.2 Prostate Cancer PARP Inhibitor Drugs Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Prostate Cancer PARP Inhibitor Drugs Sales Model

8.5.2 Sales Channel

8.5.3 Prostate Cancer PARP Inhibitor Drugs Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Takeda Pharmaceutical Company Limited

BeiGene Ltd

Jiangsu Hengrui Pharmaceuticals Co., Ltd

List of Tables

Table 1. Prostate Cancer PARP Inhibitor Drugs Market Trends

Table 2. Prostate Cancer PARP Inhibitor Drugs Market Drivers & Opportunity

Table 3. Prostate Cancer PARP Inhibitor Drugs Market Challenges

Table 4. Prostate Cancer PARP Inhibitor Drugs Market Restraints

Table 5. Global Prostate Cancer PARP Inhibitor Drugs Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Prostate Cancer PARP Inhibitor Drugs Revenue Market Share by Company (2019-2024)

Table 7. Global Prostate Cancer PARP Inhibitor Drugs Sales Volume by Company (2019-2024) & (K Units)

Table 8. Global Prostate Cancer PARP Inhibitor Drugs Sales Volume Market Share by Company (2019-2024)

Table 9. Global Market Prostate Cancer PARP Inhibitor Drugs Price by Company (2019-2024) & (US$/Unit)

Table 10. Key Manufacturers Prostate Cancer PARP Inhibitor Drugs Manufacturing Base Distribution and Headquarters

Table 11. Key Manufacturers Prostate Cancer PARP Inhibitor Drugs Product Type

Table 12. Key Manufacturers Time to Begin Mass Production of Prostate Cancer PARP Inhibitor Drugs

Table 13. Global Prostate Cancer PARP Inhibitor Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Prostate Cancer PARP Inhibitor Drugs as of 2023)

Table 15. Mergers & Acquisitions, Expansion Plans

Table 16. Global Prostate Cancer PARP Inhibitor Drugs Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 17. Global Prostate Cancer PARP Inhibitor Drugs Sales Value by Type (2019-2024) & (US$ Million)

Table 18. Global Prostate Cancer PARP Inhibitor Drugs Sales Value by Type (2025-2030) & (US$ Million)

Table 19. Global Prostate Cancer PARP Inhibitor Drugs Sales Market Share in Value by Type (2019-2024) & (%)

Table 20. Global Prostate Cancer PARP Inhibitor Drugs Sales Market Share in Value by Type (2025-2030) & (%)

Table 21. Global Prostate Cancer PARP Inhibitor Drugs Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)

Table 22. Global Prostate Cancer PARP Inhibitor Drugs Sales Volume by Type (2019-2024) & (K Units)

Table 23. Global Prostate Cancer PARP Inhibitor Drugs Sales Volume by Type (2025-2030) & (K Units)

Table 24. Global Prostate Cancer PARP Inhibitor Drugs Sales Market Share in Volume by Type (2019-2024) & (%)

Table 25. Global Prostate Cancer PARP Inhibitor Drugs Sales Market Share in Volume by Type (2025-2030) & (%)

Table 26. Global Prostate Cancer PARP Inhibitor Drugs Price by Type (2019-2024) & (US$/Unit)

Table 27. Global Prostate Cancer PARP Inhibitor Drugs Price by Type (2025-2030) & (US$/Unit)

Table 28. Global Prostate Cancer PARP Inhibitor Drugs Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 29. Global Prostate Cancer PARP Inhibitor Drugs Sales Value by Application (2019-2024) & (US$ Million)

Table 30. Global Prostate Cancer PARP Inhibitor Drugs Sales Value by Application (2025-2030) & (US$ Million)

Table 31. Global Prostate Cancer PARP Inhibitor Drugs Sales Market Share in Value by Application (2019-2024) & (%)

Table 32. Global Prostate Cancer PARP Inhibitor Drugs Sales Market Share in Value by Application (2025-2030) & (%)

Table 33. Global Prostate Cancer PARP Inhibitor Drugs Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)

Table 34. Global Prostate Cancer PARP Inhibitor Drugs Sales Volume by Application (2019-2024) & (K Units)

Table 35. Global Prostate Cancer PARP Inhibitor Drugs Sales Volume by Application (2025-2030) & (K Units)

Table 36. Global Prostate Cancer PARP Inhibitor Drugs Sales Market Share in Volume by Application (2019-2024) & (%)

Table 37. Global Prostate Cancer PARP Inhibitor Drugs Sales Market Share in Volume by Application (2025-2030) & (%)

Table 38. Global Prostate Cancer PARP Inhibitor Drugs Price by Application (2019-2024) & (US$/Unit)

Table 39. Global Prostate Cancer PARP Inhibitor Drugs Price by Application (2025-2030) & (US$/Unit)

Table 40. Global Prostate Cancer PARP Inhibitor Drugs Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Global Prostate Cancer PARP Inhibitor Drugs Sales Value by Region (2019-2024) & (US$ Million)

Table 42. Global Prostate Cancer PARP Inhibitor Drugs Sales Value by Region (2025-2030) & (US$ Million)

Table 43. Global Prostate Cancer PARP Inhibitor Drugs Sales Value by Region (2019-2024) & (%)

Table 44. Global Prostate Cancer PARP Inhibitor Drugs Sales Value by Region (2025-2030) & (%)

Table 45. Global Prostate Cancer PARP Inhibitor Drugs Sales Volume by Region (K Units): 2019 VS 2023 VS 2030

Table 46. Global Prostate Cancer PARP Inhibitor Drugs Sales Volume by Region (2019-2024) & (K Units)

Table 47. Global Prostate Cancer PARP Inhibitor Drugs Sales Volume by Region (2025-2030) & (K Units)

Table 48. Global Prostate Cancer PARP Inhibitor Drugs Sales Volume by Region (2019-2024) & (%)

Table 49. Global Prostate Cancer PARP Inhibitor Drugs Sales Volume by Region (2025-2030) & (%)

Table 50. Global Prostate Cancer PARP Inhibitor Drugs Average Price by Region (2019-2024) & (US$/Unit)

Table 51. Global Prostate Cancer PARP Inhibitor Drugs Average Price by Region (2025-2030) & (US$/Unit)

Table 52. Key Countries/Regions Prostate Cancer PARP Inhibitor Drugs Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 53. Key Countries/Regions Prostate Cancer PARP Inhibitor Drugs Sales Value, (2019-2024) & (US$ Million)

Table 54. Key Countries/Regions Prostate Cancer PARP Inhibitor Drugs Sales Value, (2025-2030) & (US$ Million)

Table 55. Key Countries/Regions Prostate Cancer PARP Inhibitor Drugs Sales Volume, (2019-2024) & (K Units)

Table 56. Key Countries/Regions Prostate Cancer PARP Inhibitor Drugs Sales Volume, (2025-2030) & (K Units)

Table 57. AstraZeneca Company Information

Table 58. AstraZeneca Introduction and Business Overview

Table 59. AstraZeneca Prostate Cancer PARP Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 60. AstraZeneca Prostate Cancer PARP Inhibitor Drugs Product Offerings

Table 61. AstraZeneca Recent Development

Table 62. Merck & Co., Inc Company Information

Table 63. Merck & Co., Inc Introduction and Business Overview

Table 64. Merck & Co., Inc Prostate Cancer PARP Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 65. Merck & Co., Inc Prostate Cancer PARP Inhibitor Drugs Product Offerings

Table 66. Merck & Co., Inc Recent Development

Table 67. GSK Company Information

Table 68. GSK Introduction and Business Overview

Table 69. GSK Prostate Cancer PARP Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 70. GSK Prostate Cancer PARP Inhibitor Drugs Product Offerings

Table 71. GSK Recent Development

Table 72. Pfizer Company Information

Table 73. Pfizer Introduction and Business Overview

Table 74. Pfizer Prostate Cancer PARP Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 75. Pfizer Prostate Cancer PARP Inhibitor Drugs Product Offerings

Table 76. Pfizer Recent Development

Table 77. Johnson & Johnson Company Information

Table 78. Johnson & Johnson Introduction and Business Overview

Table 79. Johnson & Johnson Prostate Cancer PARP Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 80. Johnson & Johnson Prostate Cancer PARP Inhibitor Drugs Product Offerings

Table 81. Johnson & Johnson Recent Development

Table 82. Takeda Pharmaceutical Company Limited Company Information

Table 83. Takeda Pharmaceutical Company Limited Introduction and Business Overview

Table 84. Takeda Pharmaceutical Company Limited Prostate Cancer PARP Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 85. Takeda Pharmaceutical Company Limited Prostate Cancer PARP Inhibitor Drugs Product Offerings

Table 86. Takeda Pharmaceutical Company Limited Recent Development

Table 87. BeiGene, Inc Company Information

Table 88. BeiGene, Inc Introduction and Business Overview

Table 89. BeiGene, Inc Prostate Cancer PARP Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 90. BeiGene, Inc Prostate Cancer PARP Inhibitor Drugs Product Offerings

Table 91. BeiGene, Inc Recent Development

Table 92. Jiangsu Hengrui Pharmaceuticals Co., Ltd Company Information

Table 93. Jiangsu Hengrui Pharmaceuticals Co., Ltd Introduction and Business Overview

Table 94. Jiangsu Hengrui Pharmaceuticals Co., Ltd Prostate Cancer PARP Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 95. Jiangsu Hengrui Pharmaceuticals Co., Ltd Prostate Cancer PARP Inhibitor Drugs Product Offerings

Table 96. Jiangsu Hengrui Pharmaceuticals Co., Ltd Recent Development

Table 97. Key Raw Materials Lists

Table 98. Raw Materials Key Suppliers Lists

Table 99. Prostate Cancer PARP Inhibitor Drugs Downstream Customers

Table 100. Prostate Cancer PARP Inhibitor Drugs Distributors List

Table 101. Research Programs/Design for This Report

Table 102. Key Data Information from Secondary Sources

Table 103. Key Data Information from Primary Sources

List of Figures

Figure 1. Prostate Cancer PARP Inhibitor Drugs Product Picture

Figure 2. Global Prostate Cancer PARP Inhibitor Drugs Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Prostate Cancer PARP Inhibitor Drugs Sales Value (2019-2030) & (US$ Million)

Figure 4. Global Prostate Cancer PARP Inhibitor Drugs Sales Volume (2019-2030) & (K Units)

Figure 5. Global Prostate Cancer PARP Inhibitor Drugs Sales Price (2019-2030) & (US$/Unit)

Figure 6. Prostate Cancer PARP Inhibitor Drugs Report Years Considered

Figure 7. Global Prostate Cancer PARP Inhibitor Drugs Players Revenue Ranking (2023) & (US$ Million)

Figure 8. Global Prostate Cancer PARP Inhibitor Drugs Players Sales Volume Ranking (2023) & (K Units)

Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Prostate Cancer PARP Inhibitor Drugs Revenue in 2023

Figure 10. Prostate Cancer PARP Inhibitor Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 11. Lynparza Picture

Figure 12. Zejula Picture

Figure 13. Talzenna Picture

Figure 14. Fluzoparib Picture

Figure 15. PamiPali Picture

Figure 16. Other Picture

Figure 17. Global Prostate Cancer PARP Inhibitor Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 18. Global Prostate Cancer PARP Inhibitor Drugs Sales Value Market Share by Type, 2023 & 2030

Figure 19. Global Prostate Cancer PARP Inhibitor Drugs Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)

Figure 20. Global Prostate Cancer PARP Inhibitor Drugs Sales Volume Market Share by Type, 2023 & 2030

Figure 21. Global Prostate Cancer PARP Inhibitor Drugs Price by Type (2019-2030) & (US$/Unit)

Figure 22. Product Picture of Hospital

Figure 23. Product Picture of Specialty Clinic

Figure 24. Product Picture of other

Figure 25. Global Prostate Cancer PARP Inhibitor Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 26. Global Prostate Cancer PARP Inhibitor Drugs Sales Value Market Share by Application, 2023 & 2030

Figure 27. Global Prostate Cancer PARP Inhibitor Drugs Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)

Figure 28. Global Prostate Cancer PARP Inhibitor Drugs Sales Volume Market Share by Application, 2023 & 2030

Figure 29. Global Prostate Cancer PARP Inhibitor Drugs Price by Application (2019-2030) & (US$/Unit)

Figure 30. North America Prostate Cancer PARP Inhibitor Drugs Sales Value (2019-2030) & (US$ Million)

Figure 31. North America Prostate Cancer PARP Inhibitor Drugs Sales Value by Country (%), 2023 VS 2030

Figure 32. Europe Prostate Cancer PARP Inhibitor Drugs Sales Value (2019-2030) & (US$ Million)

Figure 33. Europe Prostate Cancer PARP Inhibitor Drugs Sales Value by Country (%), 2023 VS 2030

Figure 34. Asia Pacific Prostate Cancer PARP Inhibitor Drugs Sales Value (2019-2030) & (US$ Million)

Figure 35. Asia Pacific Prostate Cancer PARP Inhibitor Drugs Sales Value by Country (%), 2023 VS 2030

Figure 36. South America Prostate Cancer PARP Inhibitor Drugs Sales Value (2019-2030) & (US$ Million)

Figure 37. South America Prostate Cancer PARP Inhibitor Drugs Sales Value by Country (%), 2023 VS 2030

Figure 38. Middle East & Africa Prostate Cancer PARP Inhibitor Drugs Sales Value (2019-2030) & (US$ Million)

Figure 39. Middle East & Africa Prostate Cancer PARP Inhibitor Drugs Sales Value by Country (%), 2023 VS 2030

Figure 40. Key Countries/Regions Prostate Cancer PARP Inhibitor Drugs Sales Value (%), (2019-2030)

Figure 41. Key Countries/Regions Prostate Cancer PARP Inhibitor Drugs Sales Volume (%), (2019-2030)

Figure 42. United States Prostate Cancer PARP Inhibitor Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 43. United States Prostate Cancer PARP Inhibitor Drugs Sales Value by Type (%), 2023 VS 2030

Figure 44. United States Prostate Cancer PARP Inhibitor Drugs Sales Value by Application (%), 2023 VS 2030

Figure 45. Europe Prostate Cancer PARP Inhibitor Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 46. Europe Prostate Cancer PARP Inhibitor Drugs Sales Value by Type (%), 2023 VS 2030

Figure 47. Europe Prostate Cancer PARP Inhibitor Drugs Sales Value by Application (%), 2023 VS 2030

Figure 48. China Prostate Cancer PARP Inhibitor Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 49. China Prostate Cancer PARP Inhibitor Drugs Sales Value by Type (%), 2023 VS 2030

Figure 50. China Prostate Cancer PARP Inhibitor Drugs Sales Value by Application (%), 2023 VS 2030

Figure 51. Japan Prostate Cancer PARP Inhibitor Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 52. Japan Prostate Cancer PARP Inhibitor Drugs Sales Value by Type (%), 2023 VS 2030

Figure 53. Japan Prostate Cancer PARP Inhibitor Drugs Sales Value by Application (%), 2023 VS 2030

Figure 54. South Korea Prostate Cancer PARP Inhibitor Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 55. South Korea Prostate Cancer PARP Inhibitor Drugs Sales Value by Type (%), 2023 VS 2030

Figure 56. South Korea Prostate Cancer PARP Inhibitor Drugs Sales Value by Application (%), 2023 VS 2030

Figure 57. Southeast Asia Prostate Cancer PARP Inhibitor Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 58. Southeast Asia Prostate Cancer PARP Inhibitor Drugs Sales Value by Type (%), 2023 VS 2030

Figure 59. Southeast Asia Prostate Cancer PARP Inhibitor Drugs Sales Value by Application (%), 2023 VS 2030

Figure 60. India Prostate Cancer PARP Inhibitor Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 61. India Prostate Cancer PARP Inhibitor Drugs Sales Value by Type (%), 2023 VS 2030

Figure 62. India Prostate Cancer PARP Inhibitor Drugs Sales Value by Application (%), 2023 VS 2030

Figure 63. Prostate Cancer PARP Inhibitor Drugs Industrial Chain

Figure 64. Prostate Cancer PARP Inhibitor Drugs Manufacturing Cost Structure

Figure 65. Channels of Distribution (Direct Sales, and Distribution)

Figure 66. Bottom-up and Top-down Approaches for This Report

Figure 67. Data Triangulation

Figure 68. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions